Literature DB >> 11714531

Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer.

J Zhou1, L Nong, M Wloch, A Cantor, J L Mulshine, M S Tockman.   

Abstract

We have reported that a mouse monoclonal antibody, 703D4, which recognizes heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP-A2/B1) can frequently detect lung cancer in exfoliated sputum epithelial cells 1-2 years earlier than routine chest X-ray or sputum cytomorphology. We along with others have shown that microsatellite alteration (MA) at selected loci can be recognized in sputum cells prior to clinical lung cancer. The present study was undertaken to determine how frequently the expression of hnRNP-A2/B1 message is associated with neoplastic clonal expansion as shown by MA in 41 cases of non-small cell lung cancer (NSCLC). We used Northern blotting to evaluate hnRNP-A2/B1 mRNA expression in lung tumor and remote noninvolved lung. We evaluated microsatellite instability (i.e. shifts; MI) or loss of heterozygosity (LOH) with a panel of 13 microsatellite markers at loci identified previously as susceptible in NSCLC. Of the 41 tumors, 25 (61%) over-expressed hnRNP-A2/B1 and 33 (80%) demonstrated MA in at least one of 13 loci (58% in at least two loci). The association between MA (one locus) and the overexpression of hnRNP-A2/B1 is statistically significant (P=0.0082), and those lung tumors with MA at two or more loci were significantly more likely to over-express hnRNP-A2/B1 mRNA (P=0.004). MA of loci on 3p were the only MA statistically associated with hnRNP-A2/B1 message overexpression (P=0.001). We conclude that lung tumor cells undergoing clonal expansion frequently upregulate hnRNP-A2/B1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714531     DOI: 10.1016/s0169-5002(01)00254-9

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.

Authors:  Amit Gupta; Sandhya Yadav; Archana Pt; Jharna Mishra; Atul Samaiya; Rajendra Kumar Panday; Sanjeev Shukla
Journal:  Lab Invest       Date:  2020-07-15       Impact factor: 5.662

2.  Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.

Authors:  Jinmu Deng; Song Chen; Feng Wang; Hongxin Zhao; Zongyi Xie; Zhongye Xu; Qingtao Zhang; Ping Liang; Xuan Zhai; Yuan Cheng
Journal:  Mol Neurobiol       Date:  2015-01-14       Impact factor: 5.590

Review 3.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

Review 4.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

5.  Apigenin by targeting hnRNPA2 sensitizes triple-negative breast cancer spheroids to doxorubicin-induced apoptosis and regulates expression of ABCC4 and ABCG2 drug efflux transporters.

Authors:  Meenakshi Sudhakaran; Michael Ramirez Parra; Hayden Stoub; Kathleen A Gallo; Andrea I Doseff
Journal:  Biochem Pharmacol       Date:  2020-10-02       Impact factor: 5.858

6.  Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.

Authors:  Georgios Boukakis; Meropi Patrinou-Georgoula; Maria Lekarakou; Christos Valavanis; Apostolia Guialis
Journal:  BMC Cancer       Date:  2010-08-17       Impact factor: 4.430

Review 7.  Splicing-factor alterations in cancers.

Authors:  Olga Anczuków; Adrian R Krainer
Journal:  RNA       Date:  2016-09       Impact factor: 4.942

8.  Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.

Authors:  Alessio Di Luca; Michael Henry; Paula Meleady; Robert O'Connor
Journal:  Daru       Date:  2015-08-04       Impact factor: 3.117

9.  Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.

Authors:  Asaf Shilo; Vered Ben Hur; Polina Denichenko; Ilan Stein; Eli Pikarsky; Jens Rauch; Walter Kolch; Lars Zender; Rotem Karni
Journal:  RNA       Date:  2014-02-26       Impact factor: 4.942

10.  Effect of hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells via the regulation of AKT and STAT3 pathways.

Authors:  Decheng Yin; Chengxiang Kong; Muhu Chen
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.